A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers. - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

This study has been completed.

Study NCT00423566. Last updated on January 17, 2007. Information provided by University of Oxford

Please refer to this study by its ClinicalTrials.gov identifier: NCT00423566

Locations


United Kingdom, Oxfordshire
	University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine
	Oxford, Oxfordshire, United Kingdom, OX3 7LJ

Sponsors and Collaborators

University of Oxford

Investigators


Principal Investigator:	Helen McShane, MD and PhD	University of Oxford